KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Account Payables (2024 - 2025)

Aurinia Pharmaceuticals' Change in Account Payables history spans 2 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 129.78% year-over-year to $1.1 million; the TTM value through Dec 2025 reached -$1.9 million, down 317.91%, while the annual FY2025 figure was -$1.9 million, 317.91% down from the prior year.
  • Change in Account Payables reached $1.1 million in Q4 2025 per AUPH's latest filing, up from -$1.1 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.7 million in Q2 2024 to a low of -$3.7 million in Q4 2024.